Clinical Trials Browser

Phase 2 × Multiple Myeloma × GSK2141795 × Clear all

NCT01989598 2022-03-02

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

25 enrolled 11 charts

Multiple Myeloma